Correction: SARS-CoV-2 infection is associated with self-reported post-acute neuropsychological symptoms within six months of follow-up Liana R Andronescu, Stephanie A Richard, Ann I Scher, David A Lindholm, Katrin Mende, Anuradha Ganesan, Nikhil Huprikar, Tahaniyat Lalani Tables 1 , 2 , S1 , and S2 Tables were uploaded incorrectly. Please see the correct versions below. 10.1371/journal.pone.0351062.t001 Table 1 Depression, anxiety, fatigue, self-assessed cognitive function, and general characteristics of EPICC study participants, by SARS-CoV-2 infection status. Total (N = 2383) SARS-CoV-2 negative (N = 1696) SARS-CoV-2 positive (N = 687) P-value 1 Outcomes, n (%) Depression (PHQ-9 score ≥ 10) 281 (11.8%) 175 (10.3%) 106 (15.4%) < 0.001 Anxiety (GAD-7 score ≥ 10) 279 (11.7%) 190 (11.2%) 89 (13.0%) 0.228 Fatigue (PROMIS® 7a t-score ≥ 60) 274 (11.5%) 136 (8.0%) 138 (20.1%) < 0.001 Impaired cognitive function (PROMIS® 8a t-score ≤ 40) 254 (10.7%) 146 (8.6%) 108 (15.7%) < 0.001 Impaired cognitive function abilities (PROMIS® subset 8a t-score ≤ 40) 444 (18.6%) 277 (16.3%) 167 (24.3%) < 0.001 Male, n (%) 1558 (65.4%) 1140 (67.2%) 418 (60.8%) 0.003 Ethnicity, n (%) 0.499 White 1564 (65.6%) 1120 (66.0%) 444 (64.6%) Black 159 (6.7%) 111 (6.5%) 48 (7.0%) Hispanic or Latino 318 (13.3%) 216 (12.7%) 102 (14.8%) Other 342 (14.4%) 249 (14.7%) 93 (13.5%) Active military duty, n (%) 1958 (82.2%) 1440 (84.9%) 518 (75.4%) < 0.001 Age, mean (SD) 37.5 (10.3) 37.3 (10.2) 37.9 (10.6) 0.384 BMI, mean (SD) 27.7 (4.6) 27.4 (4.4) 28.2 (5.0) <0.001 Months post symptom onset or enrollment, mean (SD) 2.4 (1.9) 2.3 (1.9) 2.7 (1.7) < 0.001 Prior diagnosis of depression and/or anxiety, n (%) 831 (34.9%) 567 (33.4%) 264 (38.4%) 0.020 Vaccine breakthrough, n (%) -- -- 476 (69.3%) COVID-19 severity, n (%) Outpatient/Asymptomatic -- -- 648 (94.3%) Hospitalized -- -- 39 (5.7%) 1 Comparing SARS-CoV-2 negative and positive groups using chi-square or Kruskal-Wallis tests. 10.1371/journal.pone.0351062.t002 Table 2 Poisson regression of potential risk factors for moderate-to-severe depression and anxiety, increased fatigue, and self-assessed cognitive impairment among SARS-CoV-2 positive participants (N = 687)- aRR (95% CI) 1 , 2 , 3 . PHQ-9 4 Depression GAD-7 5 Anxiety PROMIS® 7a 6 Fatigue PROMIS® short form 8a 7 Impaired Cognitive Function PROMIS® short form 8a 8 Impaired Cognitive Function Abilities Months post first positive test 1.04 (0.92-1.17) 0.95 (0.83-1.07) 0.94 (0.84-1.04) 1.05 (0.94-1.18) 1.03 (0.94-1.13) Male 1.00 (0.65-1.54) 0.70 (0.44-1.12) 0.69 (0.48-1.00) 0.82 (0.54-1.25) 0.86 (0.62-1.21) Race/ethnicity White REF REF REF REF REF Black 1.97 (1.00-3.59) 0.95 (0.41-1.92) 1.49 (0.84-2.47) 0.53 (0.18-1.19) 1.11 (0.6-1.89) Hispanic or Latino 1.55 (0.93-2.50) 0.69 (0.36-1.25) 1.03 (0.64-1.62) 1.02 (0.60-1.66) 1.23 (0.81-1.82) Other 0.63 (0.26-1.30) 1.05 (0.50-1.99) 1.19 (0.68-1.98) 0.76 (0.36-1.43) 0.76 (0.42-1.27) Active-duty military 0.95 (0.55-1.69) 1.12 (0.59-2.16) 1.70 (1.00-2.99) 2.33 (1.24-4.62) 1.56 (0.97-2.56) Age 1.00 (0.98-1.02) 1.01 (0.99-1.03) 1.01 (0.99-1.03) 1.02 (1-1.04) 1.02 (1.00-1.03) BMI 1.02 (0.98-1.06) 1.00 (0.96-1.04) 1.02 (0.98-1.05) 1.01 (0.97-1.05) 1.01 (0.97-1.04) Disease severity Outpatient REF REF REF REF REF Hospitalized 1.36 (0.67-2.6) 0.62 (0.21-1.49) 1.59 (0.85-2.8) 1.34 (0.61-2.7) 0.86 (0.43-1.56) Vaccine breakthrough 1.16 (0.74-1.86) 0.69 (0.42-1.13) 0.95 (0.64-1.44) 1.14 (0.72-1.84) 0.81 (0.57-1.16) Depression (PHQ-9 continuous scores) 1.19 (1.15-1.23) 1.18 (1.14-1.23) 1.14 (1.09-1.19) 1.09 (1.05-1.13) Anxiety (GAD-7 continuous scores) 1.18 (1.14-1.21) 0.97 (0.93-1.01) 1.03 (0.98-1.07) 1.04 (1.00-1.08) 1 aRR- adjusted rate ratio; CI- confidence interval. 2 All models adjusted for time since first positive test or enrollment, sex, ethnicity, active duty military, age, BMI, disease severity, vaccine breakthrough, and concurrent depression and anxiety scores from PHQ-9 and GAD-7 questionnaires. 3 Statistically significant aRR at p < 0.05 are in bold text. 4 PHQ-9 has a cutoff score of ≥10 to identify participants with moderate-to-severe depression. 5 GAD-7 has a cutoff score of ≥10 to identify participants with moderate-to-severe anxiety. 6 PROMIS® 7a Fatigue questionnaire has a cutoff of ≥60 to identify participants one standard deviation above the sample mean. 7 PROMIS® cognitive function short form 8a has a cutoff of ≤40 to identify participants one standard deviation below the sample mean. 8 PROMIS® cognitive function short form abilities 8a has a cutoff of ≤40 to identify participants one standard deviation below the sample mean. Supporting information S1 Table Poisson regression measuring the risk of moderate-to-severe depression and anxiety, increased fatigue, and self-assessed cognitive impairment by COVID-19 infection (N = 2383)- aRR (95% CI). (PDF) S2 Table Depression, anxiety, fatigue, self-assessed cognitive function, and demographics of EPICC study participants by history of anxiety and/or depression diagnosis. (PDF)